Tüdőrák: vizsgálatok itt: Törökország

In Törökország 62 Also abroad 2733

62 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Adana, Ankara, Istanbul, Kayseri, Korfez Mahallesi
Életkor
18 év and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
3. fázisTaking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Adana, Ankara, Balçova, Bornova, Istanbul, Sakarya
Életkor
18 év and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Adana, Ankara, Çiğli, Istanbul
Életkor
18 év and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
3. fázisTaking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Adana, Ankara, Diyarbakır, Istanbul, Izmir, Samsun
Életkor
18 év and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
3. fázisTaking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Altindağ, Ankara, Edirne, Istanbul, Seyhan
Életkor
18 év and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
2. fázisTaking people
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Where
Adana, Ankara, Talas
Életkor
18 év and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00
3. fázisTaking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Ankara, Istanbul
Életkor
18 év and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
3. fázisTaking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Adana, Ankara, Istanbul, Malatya, Mersin, Rize, Sakarya
Életkor
18 év and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
3. fázisTaking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Adana, Ankara, Atakum, Istanbul, Türkiye
Életkor
18 év and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
3. fázisTaking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Adana, Ankara, Çankaya, Kartal, Kayseri, Mersin, Rize
Életkor
18 év and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
3. fázisTaking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Adana, Ankara, Antalya, Istanbul, Izmir, Pendik, Sur
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
1/2. fázisTaking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Ankara, Bornova, Istanbul, Yüreğir
Életkor
18 év and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Adana, Ankara, Istanbul
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
3. fázisTaking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Adana, Adapazarı, Ankara, Istanbul, Kayseri, Sıhhiye, Tekirdağ, Trabzon
Életkor
18 év and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
1/2. fázisTaking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Adana, Ankara, Istanbul
Életkor
18 év to 64 év
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
3. fázisTaking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Adana, Ankara, Istanbul, Izmir, Kayseri
Életkor
18 év and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
3. fázisTaking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Adana, Ankara, Antalya, Aydin, Denizli, Istanbul, Izmir, Samsun
Életkor
18 év to 100 év
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Adana, Antalya, Çankaya, Istanbul
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
3. fázisTaking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bilkent Ankara, Istanbul, Izmir, Kadıköy, Küçükçekmece, Sakarya, Yenimahalle, Yüreğir
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Adana, Adapazarı, Ankara, Antalya, Edirne, Gaziantep, Istanbul, Izmir, Pendik, Samsun
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Adana, Ankara, Bornova, Denizli, Istanbul, Samsun, Stanbul, Talas
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2. fázisTaking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Istanbul, Sakarya
Életkor
18 év and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
1/2. fázisTaking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Ankara, Çankaya, Istanbul
Életkor
18 év and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Adana, Ankara, Antalya, Diyarbakır, Gaziantep, Istanbul, Izmir, Kadıköy, Keçiören, Kocaeli, Konya, Küçükçekmece, Ordu, Ortahisar, Sakarya, Samsun, Seyhan, Toroslar, Yenimahalle, Zeytinburnu
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Ankara, Antalya, Istanbul
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997